Cargando…
Glutaminase inhibition in renal cell carcinoma therapy
Receptor tyrosine kinase inhibitors have been a standard first-line therapy for renal cell carcinoma (RCC) for over a decade. Although they stabilize the disease, they are unable to remove all tumor cells, leading to relapse. Moreover, both intrinsic and acquired resistance to therapy are a signific...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
OAE Publishing Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992627/ https://www.ncbi.nlm.nih.gov/pubmed/35582719 http://dx.doi.org/10.20517/cdr.2018.004 |